Artículos con órdenes de acceso público - GARCIA-SANZ RAMÓNMás información
No disponibles en ningún lugar: 32
Revisar
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N Puig, ME Sarasquete, A Balanzategui, J Martinez, B Paiva, H Garcia, ...
Leukemia 28 (2), 391-397, 2014
Órdenes: Gobierno de España
Revisar
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
T Paíno, B Paiva, JM Sayagués, I Mota, T Carvalheiro, LA Corchete, ...
Leukemia 29 (5), 1186-1194, 2015
Órdenes: Gobierno de España
Revisar
Treatment for patients with newly diagnosed multiple myeloma in 2015
MV Mateos, EM Ocio, B Paiva, L Rosiñol, J Martínez-López, J Bladé, ...
Blood Reviews 29 (6), 387-403, 2015
Órdenes: Gobierno de España
Revisar
Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes
JM Bastida, JR González-Porras, C Jiménez, R Benito, GR Ordoñez, ...
Thrombosis and haemostasis 26 (01), 66-74, 2017
Órdenes: Gobierno de España
Revisar
Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?
B Paiva, N Puig, R García-Sanz, JF San Miguel
Clinical Cancer Research 21 (9), 2001-2008, 2015
Órdenes: Gobierno de España
Revisar
The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy
S Alonso-Álvarez, MB Vidriales, MD Caballero, O Blanco, N Puig, ...
Leukemia & lymphoma 58 (5), 1144-1152, 2017
Órdenes: Gobierno de España
Revisar
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
R García‐Sanz, I Dogliotti, GM Zaccaria, EM Ocio, A Rubio, I Murillo, ...
British Journal of Haematology 192 (5), 843-852, 2021
Órdenes: Gobierno de España
Revisar
Clinical applicability and prognostic significance of molecular response assessed by fluorescent‐PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study
J Martinez‐Lopez, E Fernández‐Redondo, R García‐Sánz, ...
British journal of haematology 163 (5), 581-589, 2013
Órdenes: Gobierno de España
Revisar
Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction
C Jiménez, M del Carmen Chillón, A Balanzategui, N Puig, E Sebastián, ...
Applied Immunohistochemistry & Molecular Morphology 22 (10), 768-773, 2014
Órdenes: Gobierno de España
Revisar
The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia
JV Jovanovic, MC Chillon, C Vincent-Fabert, R Dillon, E Voisset, ...
Leukemia 31 (3), 747-751, 2017
Órdenes: Blood Cancer UK, National Institute for Health Research, UK, Gobierno de España
Revisar
Origin of Waldenstrom's macroglobulinaemia
R Garcia-Sanz, C Jimenez, N Puig, B Paiva, NC Gutierrez, ...
Best Practice & Research Clinical Haematology 29 (2), 136-147, 2016
Órdenes: Gobierno de España
Revisar
High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma
E Sebastián, M Alcoceba, D Martín-García, Ó Blanco, M Sanchez-Barba, ...
Annals of hematology 95, 253-262, 2016
Órdenes: Gobierno de España
Revisar
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array
R García‐Sanz, LA Corchete, M Alcoceba, MC Chillon, C Jiménez, ...
Hematological Oncology 35 (4), 746-751, 2017
Órdenes: Gobierno de España
Revisar
Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study
C Jiménez, MI Prieto-Conde, M García-Álvarez, M Alcoceba, F Escalante, ...
Annals of Hematology 97, 475-484, 2018
Órdenes: Gobierno de España
Revisar
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution
N Puig, I Conde, C Jiménez, ME Sarasquete, A Balanzategui, M Alcoceba, ...
Leukemia 29 (6), 1435-1437, 2015
Órdenes: Gobierno de España
Revisar
Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real‐time quantitative PCR in patients with multiple myeloma
N Puig, ME Sarasquete, M Alcoceba, A Balanzategui, MC Chillón, ...
European Journal of Haematology 89 (4), 328-335, 2012
Órdenes: Gobierno de España
Revisar
Frequency of HLA‐A,‐B and‐DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest‐central Spain)
M Alcoceba, L Marin, A Balanzategui, ME Sarasquete, MC Chillon, ...
Tissue Antigens 78 (4), 249-255, 2011
Órdenes: Gobierno de España
Revisar
Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in …
C Santamaría, F Ramos, N Puig, E Barragán, R de Paz, C Pedro, ...
Annals of hematology 91, 1887-1895, 2012
Órdenes: Gobierno de España
Revisar
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMME n SE consortium
D Campa, A Martino, J Sainz, G Buda, K Jamroziak, N Weinhold, ...
British journal of haematology 157 (3), 331-338, 2012
Órdenes: Gobierno de España
Revisar
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin …
P Guisado-Vasco, R Arranz-Saez, M Canales, A Cánovas, ...
Leukemia & lymphoma 53 (5), 812-819, 2012
Órdenes: Gobierno de España
La información de publicación y financiación se determina de forma automática mediante un programa informático